Testing insulin production in people with type 2 diabetes
Official title: The Feasibility of an Innovative Protocol to Demonstrate the Impact of Positive Energy Balance on Pancreatic Insulin Production Capacity (PIPC)
Run by Ottawa Hospital Research Institute · NCT06462170 · Data updated 2026-11-12
This study tests how well the pancreas makes insulin in people with type 2 diabetes after they drink a meal replacement shake.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Ottawa Hospital Research Institute Academic / other |
| Locations | 1 site (Ottawa, Ontario) |
| Status | Recruiting |
| Started | June 24, 2024 |
| Main results expected | June 30, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT06462170 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older diagnosed with type 2 diabetes who are not on insulin therapy.
✕Probably not a fit
Patients with other forms of diabetes or those allergic to ingredients in the meal replacement shake may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the ability of the pancreas to produce insulin in individuals with type 2 diabetes. Participants will consume a standardized meal replacement shake, and their blood will be tested for insulin and glucose levels over a two-hour period. The study aims to measure differences in insulin production among participants and understand the underlying reasons for these differences. A total of 90 participants will be involved in this cross-sectional study, which involves a single visit for blood sampling at five time points.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of insulin production in patients with type 2 diabetes.
How similar studies have gone: While this approach is focused on insulin production capacity, similar studies have shown promise in understanding diabetes management, making this a potentially valuable investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Consent provided 2. Age \>= 18 years. 3. Diagnosed as type 2 diabetes mellitus. 4. Not on insulin therapy. Exclusion Criteria: 1. Diagnosed as another form of diabetes mellitus. 2. Allergic to one or more ingredients in Boost meal replacement shake. 3. Unable to fast since midnight and attend in person for the morning protocol.
Where it's running
-
The Ottawa Hospital
Ottawa, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Cathy Sun, MD MSc — Ottawa Hospital Research Institute
- Study coordinator: Cathy Sun, MD MSc
- Email: csun@toh.ca
- Phone: 613-738-8333
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acute Blood Flow Restriction Walking in Type 2 Diabetes
This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.
-
Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin
This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.
-
Differentiating heart disease in autoimmune vs. type 2 diabetes
This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.
-
Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses
This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.
-
Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar
This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.
-
Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes
This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.